- Home
- OP vs BIOR Comparison
OP vs BIOR Comparison
Compare OP & BIOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- BIOR
- Stock Information
- Founded
- OP 2021
- BIOR 2010
- Country
- OP Greece
- BIOR United States
- Employees
- OP N/A
- BIOR N/A
- Industry
- OP
- BIOR Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- BIOR Health Care
- Exchange
- OP Nasdaq
- BIOR Nasdaq
- Market Cap
- OP 12.5M
- BIOR 12.6M
- IPO Year
- OP N/A
- BIOR 2020
- Fundamental
- Price
- OP $1.50
- BIOR $2.34
- Analyst Decision
- OP
- BIOR Strong Buy
- Analyst Count
- OP 0
- BIOR 1
- Target Price
- OP N/A
- BIOR $150.00
- AVG Volume (30 Days)
- OP 14.4K
- BIOR 126.0K
- Earning Date
- OP 12-04-2024
- BIOR 11-14-2024
- Dividend Yield
- OP N/A
- BIOR N/A
- EPS Growth
- OP N/A
- BIOR N/A
- EPS
- OP N/A
- BIOR N/A
- Revenue
- OP $22,098,000.00
- BIOR $860,000.00
- Revenue This Year
- OP N/A
- BIOR $32,550.00
- Revenue Next Year
- OP N/A
- BIOR $95.48
- P/E Ratio
- OP N/A
- BIOR N/A
- Revenue Growth
- OP 9.82
- BIOR 777.55
- 52 Week Low
- OP $1.40
- BIOR $2.30
- 52 Week High
- OP $3.15
- BIOR $19.90
- Technical
- Relative Strength Index (RSI)
- OP 36.47
- BIOR 28.61
- Support Level
- OP $1.44
- BIOR $2.42
- Resistance Level
- OP $1.60
- BIOR $3.10
- Average True Range (ATR)
- OP 0.08
- BIOR 0.34
- MACD
- OP -0.02
- BIOR -0.02
- Stochastic Oscillator
- OP 7.41
- BIOR 3.43
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.
About BIOR Biora Therapeutics Inc.
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.